SUMMARY OF STUDIES

- Reduces aggregation of alpha synuclein 

 

- Reversal of Parkinson’s Symptoms

- Non Toxic to Nigral Dopamine Cells 

- Slow Washout Period  

- Positive results in marmoset models 

 

- Oral, IV, IM Delivery

   

- Rapid Onset of Action   

 

- Possible Neuro-protective Properties 

IPX-750 has shown very significant effects in reducing the aggregation/misfolding of the alpha-synuclein protein in studies at the University Of Alabama Birmingham (UAB) with the protein being furnished by the Mayo Clinic Jacksonville.

IPX-750 attenuates α-synuclein oligomerization.

Percent reduction in α-synuclein oligomerization, a condition that leads to Parkinson disease, was measured in response to IPX-750 treatment.

Conclusion

These combined results suggest the following:

1. That stereospecific glyconconjugation may be an effective intervention to improve penetrability of drugs     through the blood brain barrier.

2. Treatment with IPX-750 in vitro did not show evidence for neurotoxicity.

3. IPX-750 possesses possible neuroprotective effects on substantia nigral neurons in rodent models.

4. IPX- 750 possesses dopaminergic properties and exerts anti-parkinsonian effects in three different                 Parkinson’s disease rodent models and with marmoset models.

5. A Reduction and prevention of the aggregation/misfolding of the alpha synuclein protein, suggesting           therapeutic potential for this new class of drugs in treating Parkinson’s disease and other dopamine               deficiency diseases.

Learn more:

  • Facebook Social Icon
  • Twitter Social Icon
GLYCON PHARMA
CONTACT:  MIKE ALLEN
TEL:  (205) 405-4114
EMAIL:
mallen@glyconpharma.com

© 2018 by Glycon Pharma.            Powered by Bright Idea Web Design.